(Q33838248)

29 July 2017

1 reference

title

Newer agents for hormonal contraception in the male (English)

1 reference

29 July 2017

1 reference

Amory JK

1

1 reference

PubMed ID

10675892

29 July 2017

Bremner WJ

series ordinal

2

1 reference

29 July 2017

1 March 2000

1 reference

Trends in Endocrinology and Metabolism

29 July 2017

1 reference

29 July 2017

11

1 reference

29 July 2017

2

1 reference

29 July 2017

61-66

1 reference

The use of testosterone as a male contraceptive

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Androgens in men--uses and abuses

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Reversible azoospermia induced by the anabolic steroid 19-nortestosterone

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Clinical Trial of Transdermal Testosterone and Oral Levonorgestrel for Male Contraception

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071).

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Pharmacology of antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

Low dose of cyproterone acetate and testosterone enanthate for contraception in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900224-6

7 January 2021

10.1016/S1043-2760(99)00224-6

Identifiers

DOI

1 reference

release_pb2x7c3bnjcpbcnxklc2ybe74y

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pb2x7c3bnjcpbcnxklc2ybe74y

24 November 2022

mapped directly with Wikidata item

PubMed ID

10675892

1 reference

PubMed ID

10675892